The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer
Jane Antony,Elisa Zanini,Zoe Kelly,Tuan Zea Tan,Evdoxia Karali,Mohammad Alomary,Youngrock Jung,Katherine Nixon,Paula Cunnea,Christina Fotopoulou,Andrew Paterson,Sushmita Roy‐Nawathe,Gordon B Mills,Ruby Yun‐Ju Huang,Jean Paul Thiery,Hani Gabra,Chiara Recchi
DOI: https://doi.org/10.15252/embr.201745670
IF: 9.071
2018-06-15
EMBO Reports
Abstract:In ovarian cancer, the prometastatic RTK AXL promotes motility, invasion and poor prognosis. Here, we show that reduced survival caused by AXL overexpression can be mitigated by the expression of the GPI-anchored tumour suppressor OPCML Further, we demonstrate that AXL directly interacts with OPCML, preferentially so when AXL is activated by its ligand Gas6. As a consequence, AXL accumulates in cholesterol-rich lipid domains, where OPCML resides. Here, phospho-AXL is brought in proximity to the lipid domain-restricted phosphatase PTPRG, which de-phosphorylates the RTK/ligand complex. This prevents AXL-mediated transactivation of other RTKs (cMET and EGFR), thereby inhibiting sustained phospho-ERK signalling, induction of the EMT transcription factor Slug, cell migration and invasion. From a translational perspective, we show that OPCML enhances the effect of the phase II AXL inhibitor R428 <i>in vitro</i> and <i>in vivo</i> We therefore identify a novel mechanism by which two spatially restricted tumour suppressors, OPCML and PTPRG, coordinate to repress AXL-dependent oncogenic signalling.
cell biology,biochemistry & molecular biology